<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165864</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 702843-CS1</org_study_id>
    <nct_id>NCT03165864</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 702843 Administered Subcutaneously to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of
      IONIS TMPRSS6-Lrx Administered Subcutaneously for up to 44 Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events that are related to treatment with IONIS TMPRSS6-Lrx</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The safety and tolerability of single and multiple doses of IONIS TMPRSS6-Lrx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS TMPRSS6-Lrx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (maximum observed drug concentration or Cmax)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The plasma pharmacokinetics (maximum observed drug concentration or Cmax) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (time taken to reach maximal concentration or Tmax)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The plasma pharmacokinetics (time taken to reach maximal concentration or Tmax) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Plasma terminal elimination half-life (t1/2λz)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The plasma pharmacokinetics (Plasma terminal elimination half-life (t1/2λz) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the subcutaneous administration (AUCt)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The plasma pharmacokinetics (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the subcutaneous administration (AUCt) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Percentage of the administered dose excreted in urine (% Dose Excreted)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>The plasma pharmacokinetics (Percentage of the administered dose excreted in urine (% Dose Excreted) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics after single and multiple doses of IONIS TMPRSS6-Lrx (Changes in transferrin saturation)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>Effects of IONIS TMPRSS6-Lrx on changes (absolute and percent) in transferrin saturation compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics after single and multiple doses of IONIS TMPRSS6-Lrx (Changes in serum iron)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>Effects of IONIS TMPRSS6-Lrx on changes (absolute and percent) in serum iron compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics after single and multiple doses of IONIS TMPRSS6-Lrx (Changes in hepcidin levels)</measure>
    <time_frame>Up to 148 Days</time_frame>
    <description>Effects of IONIS TMPRSS6-Lrx on changes (absolute and percent) in hepcidin levels compared to baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>IONIS TMPRSS6-Lrx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline .9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS TMPRSS6-Lrx</intervention_name>
    <description>Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously</description>
    <arm_group_label>IONIS TMPRSS6-Lrx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline .9%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Healthy males or females aged 18-65 inclusive at the time of Informed Consent

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  BMI &lt; 32 kg/m2

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history or physical examination

          -  Clinically significant lab abnormalities that would render a subject unsuitable for
             inclusion

          -  Known history or positive test for HIV, HCV, or HBV

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             Screening or 5 half-lives of investigational agent, whichever is longer

          -  Smoking &gt; 10 cigarettes per day

          -  Regular excessive use of alcohol within 6 months of screening

          -  Current use of concomitant medications other than occasional acetaminophen
             (paracetamol) or ibuprofen unless approved by Sponsor Medical Monitor

          -  Considered unsuitable for inclusion by the Investigator or Sponsor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>VIC 3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeeba Aziz</last_name>
      <phone>+61 (0)3 9076 8911</phone>
      <email>a.aziz@nucleusnetwork.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassaemia, IONIS TMPRSS6-Lrx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

